Found 12 clinical trials
ADORED-Allergic Disease Onset Prevention Study
Siolta Therapeutics is testing this investigational drug for the prevention of allergic diseases, including atopic dermatitis (eczema), food allergy, asthma, and allergic rhinitis (hay fever).
- 0 views
- 13 Jan, 2025
- 9 locations
Test RTE
Study Overview Study Details Eligibility Trial Primary Objective:To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to severe atopic dermatitis (AD)Secondary Objectives:To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivationTo continue to …
- 0 views
- 19 Feb, 2024
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to severe atopic dermatitis (AD) Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation To continue to assess the …
- 0 views
- 19 Feb, 2024
- 35 locations
ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy (HeronBariatric)
Approximately 120 subjects will be randomized into 1 of the following 2 treatment groups in a 1:1 ratio:Group 1: ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will …
- 0 views
- 22 Jan, 2025
- 2 locations
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12th month of life by applying the SanaCutan Basiscreme.
- 0 views
- 19 Feb, 2024
Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
- 0 views
- 23 Jan, 2025
- 1 location
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug …
- 0 views
- 19 Feb, 2024
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Primary Objectives: To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
- 0 views
- 19 Feb, 2024
- 18 locations
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: Disease state and time course of AD, Disease state and evolution of selected atopic comorbid conditions, Effectiveness of specific AD treatments.
- 0 views
- 19 Feb, 2024
- 9 locations
Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: To characterize real-world use patterns of Dupixent for AD (eg, used regimens, reason for initiation …
- 0 views
- 19 Feb, 2024
- 19 locations
- 1
- 2